Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene

Mario T. Schellenberger, Sophie Farinelle, Stéphanie Willième, Claude P. Muller*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)


We have recently developed an experimental vaccine based on benzo[a]pyrene (B[a]P) conjugated to tetanus toxoid as a carrier protein. In combination with Freund adjuvant, this vaccine induces high levels of B[a]P-specific antibodies to protect against detrimental effects of this carcinogen. Here we evaluate this conjugate vaccine by replacing Freund adjuvant by adjuvants that are potentially compatible with their use in humans. We showed that all adjuvants tested induced specific antibodies against B[a]P and 7,8-diol-B[a]P, its carcinogenic metabolite. The best antibody levels were obtained with Quil A, MF-59 and Alum. Biological activity in terms of enhanced retention of B[a]P was confirmed in mice immunized with Quil A, Montanide, Alum and MF-59. Our findings demonstrate that a vaccination against B[a]P is feasible in combination with adjuvants licensed in humans.

Original languageEnglish
Pages (from-to)166-173
Number of pages8
JournalHuman Vaccines
Issue numberSUPPL.
Publication statusPublished - Jan 2011


  • Adjuvant
  • Benzo[a]pyrene
  • Hapten specific antibodies
  • Vaccine


Dive into the research topics of 'Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene'. Together they form a unique fingerprint.

Cite this